NIKKEI 225
27,885.87 +65.47 (+0.24%) HANG SENG
19,441.18 -77.11 (-0.40%) CRUDE OIL
73.74 -3.19 (-4.15%) GOLD FUTURES
1,783.60 +2.30 (+0.13%) DOW
33,549.70 -397.40 (-1.17%) BTC-GBP
13,943.96 -177.43 (-1.26%)
NVO Jan 2024 50.000 call
| Previous close | 63.20 |
| Open | 63.20 |
| Bid | 56.50 |
| Ask | 61.50 |
| Strike | 50.00 |
| Expiry date | 2024-01-19 |
| Day's range | 63.20 - 63.20 |
| Contract range | N/A |
| Volume | |
| Open interest | 7 |
- Globe Newswire
Novo Nordisk A/S – Share repurchase programme
Bagsværd, Denmark, 5 December 2022 – On 4 November 2022, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 24 billion to be executed during a 12-month period beginning 2 February 2022. Under the programme
- Zacks
Beat the Market Like Zacks: Novo Nordisk, Axon, General Mills in Focus
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
- Zacks
Rigel (RIGL) Up on FDA Nod to Blood Cancer Drug Rezlidhia
The FDA approves Rigel's (RIGL) Rezlidhia (olutasidenib) for treating relapsed/refractory acute myeloid leukemia with a susceptible IDH1 mutation. Stock up.
